Promising Developments for Praxis Precision Medicines
BOSTON, Dec. 04, 2025 – Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a pioneering biopharmaceutical company, has achieved a significant milestone by successfully completing a pre-NDA (New Drug Application) meeting with the FDA. This meeting included valuable feedback from the agency and a face-to-face discussion, showcasing the potential of ulixacaltamide as a treatment for essential tremor.
A Collaborative Approach
"We are thrilled with the constructive dialogues we had with the FDA, which paves the way for the submission of our first NDA early in 2026,” stated Marcio Souza, the president and chief executive officer of Praxis. “Building on the outstanding momentum from our Essential3 program, ulixacaltamide demonstrated compelling improvements in daily functioning, moving us closer to offering a much-needed therapy for the millions of individuals affected by essential tremor who currently lack effective and safe treatment options."
Understanding Essential Tremor
Essential tremor is recognized as the most prevalent movement disorder globally, impacting approximately seven million individuals in the United States alone. This disorder represents a vast commercial opportunity, as it is characterized by involuntary and rhythmic movements in the upper limbs, and often extends to other areas of the body, including the head and vocal cords. These tremors can significantly impair everyday living and are progressive, typically worsening over time.
Current Treatment Landscape
The only FDA-approved pharmacotherapy for essential tremor is propranolol, a beta-blocker that often yields limited efficacy and can lead to poor tolerability. Many patients with comorbidities are unable to use propranolol due to contraindications. As a result, off-label medications such as other beta-blockers and anti-convulsants have emerged, yet they also fall short in providing effective treatment options.
Remarkably, data revealed through patient surveys indicate that around 77% of individuals with essential tremor feel that their condition is not adequately managed, with approximately 50% not receiving any form of treatment. This glaring need for more effective treatments is echoed by neurologists, who report that 85% of their consultations involve patients seeking assistance for essential tremor, while 40% of these patients are currently untreated.
The Role of Ulixacaltamide
Ulixacaltamide emerges as a groundbreaking and highly selective small molecule inhibitor of T-type calcium channels. Its design focuses on blocking abnormal neuronal burst firing within the specific neurocircuits associated with tremor activity, specifically the Cerebello-Thalamo-Cortical (CTC) circuit. As Praxis' most advanced candidate in the Cerebrum™ small molecule platform, ulixacaltamide offers hope for transforming the treatment landscape for essential tremor.
Praxis' Vision and Commitment
Praxis Precision Medicines is dedicated to creating progressive therapies informed by genetic insights. By harnessing knowledge from genetic epilepsies, the company strives to develop treatments for CNS disorders characterized by a imbalance of neuronal excitation and inhibition. Its innovative approach includes developing therapies for both rare and common neurological conditions through proprietary platforms like Cerebrum™ and Solidus™, which utilize an in-depth understanding of shared biological targets and brain circuitry.
With a diverse portfolio and multiple clinical-stage product candidates, Praxis is making remarkable strides across movement disorders and epilepsy, indicating a commitment to addressing the unmet needs of patients lacking effective therapies.
Frequently Asked Questions
What is the significance of the recent FDA meeting for Praxis?
The FDA meeting marks a critical step in the approval process for ulixacaltamide, providing feedback that aligns with Praxis' plans for submission.
How many people are affected by essential tremor?
Approximately seven million people in the United States are affected by essential tremor, highlighting the need for effective treatment alternatives.
What challenges do current treatments for essential tremor face?
Current treatments like propranolol often experience limitations in efficacy and tolerability, with many patients unable to use them due to specific health concerns.
How does ulixacaltamide work?
Ulixacaltamide is designed to inhibit T-type calcium channels, targeting the neuro circuitry associated with tremor activity, which may enhance treatment outcomes.
What is Praxis’ broader mission?
Praxis aims to translate genetic insights into innovative therapies for CNS disorders, advancing understanding and treatment options for patients with various neurological conditions.
